CyFlow CD105 Purified
品番 | AP974049 | ||
---|---|---|---|
抗体名 | Anti-Ms CD105 PURI,MJ7/18 | ||
包装単位 | 0.1 mg | ||
濃度 | 1 mg/ml | ||
容量 | 0.1 ml | ||
関連製品 (アイソタイプコントロール) |
- | ||
反応性|交差吸着 | Mouse | レーザー | |
抗原 | CD105, Endoglin | 最大蛍光波長 | - |
クローン | MJ7/18 | 最大励起波長 | - |
ホスト | Rat | 標識/Format | Purified |
アイソタイプ | IgG2a | 研究分野 | Immunophenotyping | MHC |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Ms CD105 PURI,MJ7/18
特異性
The rat monoclonal antibody MJ7/18 recognizes CD105 antigen, a 90 kDa type I homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal (bone?) marrow and erythroid precursors in fetal and adult bone marrow.
抗原情報
CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFβR-2 as a receptor for TGFβ-1 and TGFβ-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonizes the inhibitory effects of TGFβ-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Cho SK, Bourdeau A, Letarte M, Zúñiga-Pflücker JC: Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood. 2001·Dec·15; 98(13):3635‑42. <·PMID:·11739167·>
• Dassler K, Roohi F, Lohrke J, Ide A, Remmele S, Hütter J, Pietsch H, Pison U, Schütz G: Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high‑relaxivity CD105‑specific iron oxide nanoparticles. Invest·Radiol. 2012·Jul; 47(7):383‑91. <·PMID:·22659596·>
• Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M: Targeting cancer vasculature via endoglin/CD105: a novel antibody‑based diagnostic and therapeutic strategy in solid tumours. Cardiovasc·Res. 2010·Apr·1; 86(1):42625. <·PMID:·19812043·>
• Herouet C, Cottin M, LeClaire J, Enk A, Rousset F: Contact sensitizers specifically increase MHC class II expression on murine immature dendritic cells. In·Vitr·Mol·Toxicol. 2000·Summer; 13(2):113‑23. <·PMID:·11031322·>
• Rosu-Myles M, She YM, Fair J, Muradia G, Mehic J, Menendez P, Prasad SS, Cyr TD: Identification of a candidate proteomic signature to discriminate multipotent and non‑multipotent stromal cells. PLoS·One. 2012; 7(6):e38954. <·PMID:·23266721·>
• Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF‑beta1 signalling in murine and human endothelial cells. Anticancer·Res. 2005·May-Jun; 25(3B):1851‑64. <·PMID:·16158917·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN